TREATMENT AND PROGNOSIS

HN cannot be targeted with any specific medical treatment. Control of hypertension and proteinuria through renin-angiotensin blockade may slow the progression of glomerulosclerosis and renal insufficiency. The rate of progression to ESRD varies widely and depends on the severity of the genetic mutation.

TBMN is generally a nonprogressive disease and does not result in significant scarring of the kidney. No directed therapy is needed. If a patient presumptively diagnosed with TBMN shows evidence of progressive renal disease, a renal biopsy or the other diagnostic tests mentioned previously should be considered to exclude HN and IgA nephropathy.